Proangiogenic growth factor therapy for the treatment of refractory angina: a meta-analysis

HIGHLIGHTS

• who: Deshan Weeraman MD from the CentreQueen Mary University of have published the research work: Proangiogenic Growth Factor Therapy for the Treatment of Refractory Angina: A Meta-analysis, in the Journal: (JOURNAL)
• what: The analysis showed significant decreased risk of MACE (OR 0.72; 95% confidence interval 0.55-0.93) and significantly improved CCS class (SMD 0.55; 95% CI 1.10 to 0.00) but not mortality (OR 0.66; 95% CI 0.28-1.54) or exercise tolerance (SMD 0.47; 95% CI 0.14 to 1.09) in treated patients compared . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.